Abbott Laboratories ABT reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.The company reported second-quarter sales of $11.14 billion, beating the consensus of $11.07 billion. The U.S. MedTech giant reported adjusted earnings of $1.26, beating the consensus of $1.25, and within the management guidance of $1.23-$1.27."Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS gro ...

Philips Cardiac Workstation July 17, 2025 Anumana's FDA-cleared LEF algorithm becomes first certified third-party solution available through Philips’ ECG ecosystem CAMBRIDGE, Mass. — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the Philips ECG AI Marketplace, a platform that gives cardiac care teams access to multiple vendor offerings all in one central location to help clinicians manage and implement AI-powered diagnostic tools more easily. ...

Johnson & Johnson (JNJ 6.09%) reported Q2 2025 earnings on July 16, 2025, posting sales of $23.7 billion (up 4.6%), with adjusted EPS of $2.77 and net earnings of $5.5 billion. Management raised full-year 2025 sales guidance by $2 billion and adjusted EPS guidance by $0.25, citing robust operational momentum across innovative medicine and medtech. The following insights examine how strategic execution, diversified growth drivers, and pipeline achievements are shaping the company's long-term investment profi ...

BROSSARD, Quebec, July 16, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Canadian leader in artificial intelligence (AI) for the early detection of retinal and systemic diseases, is proud to announce that it has formally submitted a Pre-Submission (Q-sub) to the U.S. Food and Drug Administration (FDA) for its flagship CARA System. This filing marks the first strategic step toward regulatory clearance and commercial deployment in the U.S ...

Carlsmed, a medical technology company that uses AI to personalize spine surgery, is seeking to raise as much as $107.2 million in a US IPO https://t.co/Z5je1FkV3q ...

Company Leadership Transition - Steven Pfanstiel has been appointed as the new Chief Financial Officer of Neuronetics, effective July 15, 2025, replacing Steve Furlong, who will retire on March 31, 2026 [2][3] - Steve Furlong will continue to serve as Senior Advisor to the CEO during the transition period to ensure operational continuity [2][3] Executive Background - Steven Pfanstiel brings over two decades of healthcare experience, having previously served as CFO and COO at Marinus Pharmaceuticals, where he was instrumental in the launch of the flagship product, Ztalmy [3][4] - Pfanstiel has held senior financial roles at various high-growth healthcare companies, including Lifescan and Optinose, and has experience at Johnson & Johnson across multiple product categories [3][4] Strategic Vision and Growth - Neuronetics aims to expand access to mental health treatments and deliver sustainable growth, leveraging Pfanstiel's expertise in financial leadership and growth strategies [3][4] - The company is focused on integrating Greenbrook operations and achieving positive cash flow in the third quarter of 2025, marking a significant operational milestone [5] Stock Incentives - As part of his employment agreement, Pfanstiel received an inducement grant of 400,000 restricted stock units, with specific vesting schedules tied to his continued employment [4] Company Performance and Market Position - Neuronetics reaffirms its guidance for the second quarter and full year 2025, driven by successful integration efforts and key growth drivers [5] - The company operates Greenbrook TMS treatment centers across the U.S., offering NeuroStar Advanced Therapy, which has delivered over 7.4 million treatments for major depressive disorder (MDD) [6][7]

Core Insights - The World Artificial Intelligence Conference (WAIC) 2025 will focus on AI's role in transforming the healthcare industry, addressing challenges from data governance to clinical application [3][25] - The event will feature multiple forums discussing key areas such as diagnostic innovation, AI drug development, clinical applications, and healthcare accessibility [3][5] Group 1: Event Details - WAIC 2025 will take place from July 26 to July 28, 2025, at the Shanghai World Expo Center and the Shanghai World Expo Exhibition Hall [3] - The exhibition area will exceed 70,000 square meters, showcasing over 30 healthcare technologies and products [17] Group 2: Key Forums and Discussions - The healthcare segment will include four major forums focusing on AI's impact on medical diagnostics, drug development, clinical applications, and equitable healthcare [3][5] - A forum titled "AI Empowering New Paradigms in Medicine and Health" will feature discussions led by Nobel laureates and Turing Award winners on transformative research and drug development [5][14] Group 3: Innovations and Technologies - The conference will unveil several technological advancements, including AI-driven drug development optimization solutions and global medical imaging AI analysis platforms [15] - Notable companies like Alibaba and Ant Group will present innovative AI medical imaging diagnostic systems [18] Group 4: Global Participation - The event will gather international research institutions, hospitals, and universities, including the Royal Academy of Engineering and Stanford University School of Medicine [9][11] - Experts from various fields will engage in high-level dialogues on the application of AI in healthcare, addressing macro industry development and clinical applications [6][25]

Group 1 - Integra LifeSciences Holdings Corporation will release its second quarter 2025 financial results on July 31, 2025, before the market opens [1] - A conference call hosted by Integra's management team will take place at 8:30 a.m. ET on the same day [1] - A live webcast of the conference call will be available on the Investors section of the company's website [2] Group 2 - Integra LifeSciences is focused on restoring patients' lives through innovative treatment pathways and advancing patient outcomes [3] - The company offers a comprehensive portfolio of high-quality, leadership brands in surgical, neurologic, and regenerative care [3] - For more information about Integra and its products, the company encourages visiting its website [3]

Core Insights - Sanara MedTech Inc. has launched a pilot program through its subsidiary Tissue Health Plus (THP) aimed at providing value-based wound care solutions for chronic wounds across six states [1][2] - The THP technology platform will serve as a Wound Care Operating System for a provider group, utilizing Co-Pilot software to standardize patient care and streamline administrative processes [2] - The pilot program is expected to validate and optimize the THP technology platform through real-world patient encounters, with plans for expansion to additional practitioners and locations [2] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing technologies to improve clinical outcomes and reduce healthcare costs in surgical and chronic wound markets [4] - The company markets a range of surgical and wound care products primarily in the North American market, including CellerateRX Surgical Activated Collagen and various antimicrobial solutions [4][5] - THP aims to transform the $100+ billion wound care market by addressing gaps in chronic wound care, with a goal of improving healing rates to over 85% and reducing total care costs by more than 25% [3] Technology and Innovation - THP's platform combines AI-powered clinical decision support, virtual care coordination, and an integrated provider network to deliver personalized wound care [3] - The pilot program is part of a broader strategy to engage with payers and financial partners to support the implementation of THP's value-based care solutions [2][3]

MONSEY, N.Y., July 14, 2025 (GLOBE NEWSWIRE) --  The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Monogram Technologies, Inc. (Nasdaq: MGRM) (“Monogram”) to Zimmer Biomet for an upfront payment of $4.04 per share in cash, and a non-tradeable contingent value right (CVR) entitling the holder to receive up to $12.37 per share in cash if certain product development, regulatory, and revenue milestones are achieved through 2030. At least two investors have already express ...